Medicine Marrow Pg 111-120 (Hematology)
50 Questions
0 Views

Medicine Marrow Pg 111-120 (Hematology)

Created by
@ArdentHouston

Podcast Beta

Play an AI-generated podcast conversation about this lesson

Questions and Answers

What is the most common mutation associated with Essential Thrombocytosis (ET)?

  • MPL mutation
  • CALR mutation
  • JAK-2 mutation (correct)
  • None of the above

    • Essential Thrombocytosis has a higher risk of conversion to Myelofibrosis compared to Polycythemia Vera.

    False

    What age group is most commonly affected by Essential Thrombocytosis?

    50-60 years

    In Essential Thrombocytosis, the platelet count is greater than _____ Lakhs.

    <p>4.5</p> Signup and view all the answers

    Match the following complications and their associated risks of conversion:

    <p>Essential Thrombocytosis = Least risk of conversion Polycythemia Vera = Highest risk of conversion Primary Myelofibrosis = Middle risk of conversion</p> Signup and view all the answers

    What is a key feature in the diagnosis of myeloproliferative neoplasms?

    <p>Normal RBC and WBC counts</p> Signup and view all the answers

    A sustained platelet count greater than 4.5 lakhs is indicative of reactive thrombocytosis.

    <p>False</p> Signup and view all the answers

    What is the primary mutation considered in the treatment algorithm for myeloproliferative neoplasms?

    <p>JAK-α mutation</p> Signup and view all the answers

    In low-risk management of myeloproliferative neoplasms, the first-line treatment is ______.

    <p>Aspirin</p> Signup and view all the answers

    Match the following treatments with their effectiveness in low-risk myeloproliferative neoplasms:

    <p>Aspirin = First-line treatment Hydroxyurea = Second-line treatment Interferon = Third-line treatment Anagrelide = Least preferred option</p> Signup and view all the answers

    Which chromosome is associated with the BCR gene?

    <p>Chromosome 22</p> Signup and view all the answers

    The Philadelphia (Ph) chromosome is present in 50% of chronic myeloid leukemia cases.

    <p>False</p> Signup and view all the answers

    What is the result of the BCR-ABL translocation in chronic myeloid leukemia?

    <p>Constitutively activated ABL kinase</p> Signup and view all the answers

    The process of myelopoiesis involves the transformation of myeloblasts into __________.

    <p>mature neutrophils</p> Signup and view all the answers

    Match the genetic components with their associated features:

    <p>ABL gene = Located on chromosome 9 BCR gene = Located on chromosome 22 Philadelphia chromosome = Shortened long arm of chromosome 22 Myristoyl binding site = Absent in translocation</p> Signup and view all the answers

    What does an elevated Tryptase level indicate?

    <p>Diagnosis of hematological neoplasm</p> Signup and view all the answers

    A low LAP score is associated with conditions such as PNH and CML.

    <p>True</p> Signup and view all the answers

    What is the significance of conventional karyotyping in CML?

    <p>To rule out abnormalities such as double Philadelphia chromosome and trisomy 8.</p> Signup and view all the answers

    In the bone marrow study for CML, it is important to quantify __________.

    <p>blasts</p> Signup and view all the answers

    Match the following tests with their purposes:

    <p>Peripheral Smear = Identify anemia and leukocytosis Flow Cytometry = Determine cell characteristics FISH = Detect BCR-ABL gene Molecular Genetics = Quantitative analysis of BCR-ABL</p> Signup and view all the answers

    What is the recommended dose of Imatinib for a chronic phase?

    <p>400 mg</p> Signup and view all the answers

    A complete cytogenic response (CCR) indicates the presence of the Philadelphia chromosome in the bone marrow.

    <p>False</p> Signup and view all the answers

    Name one tyrosine kinase inhibitor used for treating chronic phases.

    <p>Imatinib</p> Signup and view all the answers

    The primary goal of using hydroxyurea is to ↓ cell _______.

    <p>turnover</p> Signup and view all the answers

    Match the following tyrosine kinase inhibitors with their respective doses:

    <p>Imatinib = 400 mg Nilotinib = 300 mg BID Dasatinib = 100 mg/day Ponatinib = 45 mg/day</p> Signup and view all the answers

    What is one of the major criteria for diagnosing myeloproliferative neoplasms?

    <p>Hb: &gt;16.5 g/dL in men and &gt;11.6 g/dL in women</p> Signup and view all the answers

    A subnormal serum erythropoietin level is considered a minor criterion for the diagnosis of myeloproliferative neoplasms.

    <p>True</p> Signup and view all the answers

    Name one mutation associated with primary myelofibrosis.

    <p>JAK-2 mutation</p> Signup and view all the answers

    In low-risk management of myeloproliferative neoplasms, patients are advised to undergo ______ and take aspirin.

    <p>phlebotomy</p> Signup and view all the answers

    Match the following mutations associated with primary myelofibrosis to their prevalence:

    <p>JAK-2 mutation = 50% Calreticulin (CALR) = 30-40% MPL gene mutation = 10-20% Triple negative PMF = Poor prognosis</p> Signup and view all the answers

    What characteristic is typically seen in a peripheral smear of a patient with myeloproliferative neoplasms?

    <p>Leukoerythroblastosis with teardrop red cells</p> Signup and view all the answers

    A dry tap on bone marrow aspirate is a common finding in myeloproliferative neoplasms.

    <p>True</p> Signup and view all the answers

    What is the median survival for patients with myeloproliferative neoplasms?

    <p>5 years</p> Signup and view all the answers

    Peripheral smear may show ____________, which includes immature myeloid cells and nucleated red blood cells.

    <p>leukoerythroblastosis</p> Signup and view all the answers

    Match the following types of megakaryocytes with their associated conditions:

    <p>Staghorn = Essential Thrombocytosis (ET) Dwarf = Chronic Myeloid Leukemia (CML) Giant = Immune Thrombocytopenic Purpura (ITP)</p> Signup and view all the answers

    What is a common clinical feature of chronic myeloproliferative neoplasm in the chronic phase?

    <p>Asymptomatic leukocytosis</p> Signup and view all the answers

    Blast crisis in myeloproliferative neoplasms is characterized by more than 20% blasts in the blood or marrow.

    <p>True</p> Signup and view all the answers

    What is the typical 5-year survival rate for patients with chronic myeloproliferative neoplasms?

    <p>85-90%</p> Signup and view all the answers

    ___ is a common consequence of high cell turnover in myeloproliferative neoplasms, leading to joint issues.

    <p>Acute gouty arthritis</p> Signup and view all the answers

    Match the following symptoms with their associated conditions or effects:

    <p>Massive splenomegaly = Extramedullary hematopoiesis Fatigue = Anemia due to cytokines Unexplained fever = Blast crisis High white blood cell count = Asymptomatic leukocytosis</p> Signup and view all the answers

    What is a characteristic clinical feature observed in myeloproliferative neoplasms?

    <p>Massive splenomegaly</p> Signup and view all the answers

    Pancytopenia in myeloproliferative disorders can lead to fatigue, bleeding, and gout.

    <p>True</p> Signup and view all the answers

    What skin condition is characterized by febrile neutrophilic dermatosis?

    <p>Sweet syndrome</p> Signup and view all the answers

    Individuals over _____ years old are primarily affected by myeloproliferative neoplasms.

    <p>60</p> Signup and view all the answers

    Match the following clinical features with their associated conditions:

    <p>Thrombosis = Increased risk in PCRV &gt; ET &gt; PMF B-Symptoms = Fever, night sweats, weight loss Pancytopenia = Anemia, bleeding, gout Skin lesions = Febrile neutrophilic dermatosis</p> Signup and view all the answers

    Which of the following findings is noted in the bone marrow aspirate of myeloproliferative neoplasms?

    <p>Predominant granulopoiesis</p> Signup and view all the answers

    Increased dwarf megakaryocytes is a finding in myeloproliferative neoplasms.

    <p>True</p> Signup and view all the answers

    What is the significance of the presence of sea blue histiocytes in myeloproliferative neoplasms?

    <p>They are indicative of Gaucher cells.</p> Signup and view all the answers

    In the accelerated phase of myeloproliferative neoplasms, basophilia is defined as greater than _____%.

    <p>20</p> Signup and view all the answers

    Match the following prognostic scales with their elements:

    <p>Hasford Prognostic Scale = Circulating blasts Sokal Index = Platelet count Age = Hasford Prognostic Scale Eosinophils and basophils in blood = Hasford Prognostic Scale</p> Signup and view all the answers

    Study Notes

    Chronic Myeloid Leukemia

    • Pathophysiology:
      • Myeloid cells: eosinophil, basophil, RBC, platelets, monocyte.
      • Myelopoiesis: myeloblast → promyelocyte → myelocyte → metamyelocyte → band forms → segmented forms → mature neutrophils.
      • Molecular genetics: Long arm of chromosome 9 (ABL gene).
      • Molecular genetics: Long arm of chromosome 22 (BCR gene).
      • BCR-ABL fusion gene: Created by a translocation between chromosomes 9 and 22.
      • Philadelphia (Ph) chromosome: Shortening of the long arm of chromosome 22.
      • Constitutively activates ABL kinase: This activation is a result of the translocation.
      • Act as a docking site of ATP: This change is caused by the translocation.
      • Tyrosine phosphorylation: Occurs because of the above changes.

    Essential Thrombocytosis (ET)

    • Benign disease: Typically has a good prognosis.
    • Etiology:
      • JAK-2 mutation (50-60%)
      • CALR mutation (30-40%)
      • MPL mutation (10-20%)
    • Clinical features:
      • Mild splenomegaly
      • Thrombosis (due to hyperplasia)
      • Bleeding (due to dysplastic cells)
      • Female > Male
      • Age: 50-60 years
    • Investigations:
      • RBC: Normal
      • WBC: Normal
      • Platelet count (PLC): >4.5 lakhs
      • Bone marrow biopsy: Megakaryocytes show hyperplasia (few dysplastic)
      • Staghorn cells: Giant cells with mature cytoplasm, hyperlobulated nuclei.
    • Management:
      • Low Risk: Aspirin, Hydroxyurea, interferon, anagrelide.
      • High Risk: Hydroxyurea, Ruxolitinib.
    • Complications:
      • Myelofibrosis
      • AML (Acute myeloid leukemia) (PCRV > PMF > ET)
    • Note: PCRV stands for Polycythemia vera, PMF for primary myelofibrosis.

    CML Management

    • Investigations:
      • Peripheral smear:
        • RBC: Anemia
        • WBC: Increased (1 lakh)
        • Blast forms: Less than 5%
        • Myelocyte (maximum): Myelocyte bulge
        • All stages seen
        • Eosinophilia
        • Basophilia
        • Thrombocytosis (No hemorrhage/thrombosis)
      • LAP (Leukocyte Alkaline Phosphatase): Low (Cytochemical abnormal WBC)
      • Tryptase: Increased
      • Bone marrow study:
        • Conventional karyotyping (mandatory): To rule out abnormalities (Double ph, trisomy 8, isochromosome 17, Deletion of 20q)
        • Quantify blasts.
        • To determine degree of fibrosis.
    • Current methods:
      • Chronic phase + second abnormality → Bad prognosis (Double PH, isochrome 17, trisomy 8)
      • All other conditions: Prognosis assessment after Rx (TKI).
    • Management:
      • Hydroxyurea: To ↓ cell turnover
      • Tyrosine Kinase inhibitors (TKIs):
        • Imatinib (Gleevec): 400 mg: Chronic phase. 600-800 mg: Blast crisis.
        • Bosutinib: 500 mg/day
        • Nilotinib: 300 mg BID
        • Dasatinib: 100 mg/day
        • Ponatinib: 45 mg/day
        • Asciminib: -

    Primary Myelofibrosis (PMF)

    • Etiology:
      • JAK-2 mutation: 50%
      • Calreticulin (CALR): 30-40%
      • MPL gene mutation (Codes for thrombopoietin): 10-20%
      • Triple negative PMF: Absence of above mutations (Poor prognosis)
      • Deletion 13q.
    • Clinical Features:
      • Age: Primarily over 60 years old.
      • Gender: Male and female equally affected.
      • Thrombosis: Increased risk in cases of PCRV > ET > PMF.
      • B-Symptoms (20%): Fever, night sweats, weight loss.
      • Pancytopenia:
        • Anemia: Fatigue is a common symptom.
        • Bleeding
        • Gout: During proliferation stage.
        • Extramedullary hematopoiesis
        • Osteosclerosis
      • Skin: Febrile neutrophilic dermatosis (Sweet syndrome)
      • Organs: Massive splenomegaly (75%) and hepatomegaly (portal hypertension).
    • Investigations:
      • Peripheral smear:
        • Leukoerythroblastosis (immature myeloid cells CD34+, nucleated red cells)
        • Anisocytosis and poikilocytosis with teardrop red cells (dacryocytes)
        • Thrombocytosis: Cloud-like megakaryocytes
      • Serum type-III procollagen peptide: Increased
      • Bone marrow aspirate: Dry tap
      • Bone marrow biopsy:
        • Silver impregnation: Reticulin fibrosis + collagen fibrosis
        • Fibrosis with hypercellular marrow
    • Management:
      • Medical treatment:
        • Oral Ruxolitinib: In JAK-2 mutation
        • Lenalidomide
      • Definitive treatment:
        • Allogenic hematopoietic stem cell transplant (AHSCT)
        • Limitations: Complete match required, Increased risk of infection.
    • Complications:
      • Transformation to AML: 10-20%

    Polycythemia Vera (PCRV)

    • Diagnosis: WHO criteria → 3 major (or) a major + 1 minor criteria.
      • Major criteria:
        • Hb: >16.5 g/dL in men and >11.6 g/dL in women.
        • Bone marrow: Hypercellularity.
        • JAK-2 mutation.
      • Minor criteria: Subnormal serum erythropoietin level.
    • Management:
      • Low risk: Phlebotomy + Aspirin 75 mg + JAK inhibitor: Ruxolitinib 10 mg BD or Hydroxyurea: 0.5-2 g/day.
    • Prognosis:
      • Hasford Prognostic Scale:
        • Circulating blasts
        • Spleen size
        • Platelet count
        • Age
        • Eosinophils and basophils in blood
      • Sokal Index
    • Clinical Features:
      • Symptomatic: Headaches, fatigue, dizziness, tinnitus, blurry vision, night sweats, pruritis.
    • Investigations:
      • Bone Marrow Aspirate:
        • Marked hypercellularity
        • Predominant granulopoiesis (30:1)
        • Erythropoiesis: Decreased
      • Other Findings:
        • Megakaryocytes (Dwarf): Increased
        • Sea blue histiocytes (Gaucher cells): Present
        • Fibrosis: Increased
    • Peripheral smear:
      • Erythrocytosis: Increased RBC count
      • Hypersegmentation of neutrophils
      • Basophilia
      • Thrombocytosis

    Chronic Myeloid Leukemia (CML)

    • Risk factors:
      • Age: 50-60 years
      • Gender: Male > Female
      • High dose ionizing radiation (6-8 years)
      • Germ line susceptibility: very low
    • 5-Year Survival Rate: 85-90%
    • Clinical Features:
      • Chronic Phase:
        • Asymptomatic leukocytosis (WBC ~ 1 lakh):
          • Fatigue due to anemia
          • Massive splenomegaly: abdominal distension, left upper quadrant and shoulder pain, early satiety
        • Loss of appetite
        • Acute gouty arthritis: Hyperuricemia (↑ cell turnover)
        • Acne/urticaria/pruritis: ↑ basophils (Histamine release)
        • B-symptoms (10-15%): Fever, weight loss, night sweats.
      • Blast Crisis:
        • Blast ≥20% in blood/marrow
        • Present in untreated cases within 4 years.
        • Extramedullary blast proliferation
        • Unexplained fever
        • Bone pain
        • Bleeding (↓ PLC)
    • Note:
      • B-symptoms: Classically seen in Hodgkin's disease.
      • If WBC > 2 lakh: Symptoms of hyperviscosity (headache, blurring of vision, priapism, vertigo).
    • Pathogenesis:
      • Myeloproliferation (Hypercellular marrow): Dysplastic megakaryocytes (lack CXCR4 receptors) lead to marrow fibrosis (increased type-III collagen).
      • Release of precursor cells: Leads to leukoerythroblastosis in the peripheral smear.
    • Management:*
      • Tyrosine kinase inhibitors (TKIs):
        • Act on MBS.
        • Imatinib, Asciminib.
    • Prognosis:
      • Hasford Prognostic Scale:
        • Circulating blasts
        • Spleen size
        • Platelet count
        • Age
        • Eosinophils and basophils in blood
      • Sokal Index
    • Miscellaneous
      • Marrow 8.0
      • 2024
      • Scanned with OKEN Scanner

    Studying That Suits You

    Use AI to generate personalized quizzes and flashcards to suit your learning preferences.

    Quiz Team

    Description

    This quiz covers the pathophysiology and molecular genetics of Chronic Myeloid Leukemia (CML) and Essential Thrombocytosis (ET). Key topics include myelopoiesis, BCR-ABL fusion gene, and the various mutations associated with ET. Test your knowledge on these hematological conditions.

    More Like This

    Use Quizgecko on...
    Browser
    Open
    Browser
    Browser